European journal of medical research · 2025
Ulinastatin inhibits macrophage M1 polarization to improve acute pancreatitis-associated intestinal barrier dysfunction by promoting Nrf2 signaling pathway activation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Qi, Fang Jiahui, Zhang Siqi, Gao Ming
Аннотация
BACKGROUND: Intestinal barrier dysfunction plays a significant role in the development of pancreatic necrosis and multiple organ failure in AP. This study aimed to investigate the therapeutic effects and potential mechanisms of ulinastatin (UTI) on L-arginine-induced acute pancreatitis (AP)-associated intestinal barrier dysfunction in rats.
METHODS: Experimental rats were randomly divided into five subgroups as follows: control, AP, AP + UTI, AP + ML-385 and AP + UTI + ML-385. The pancreatic and intestinal injuries were assessed by enzyme-linked immunosorbent assay (ELISA), western blot, pathology, laser Doppler and transmission electron microscope (TEM). The inflammatory biomarkers were determined by western blot and the indicators of oxidative stress were also measured. The Nrf2 signaling pathway and macrophage polarization were evaluated by immunofluorescence staining, western blot and qRT-PCR analysis.
RESULTS: Ulinastatin treatment effectively improved both AP and AP-associated intestinal barrier dysfunction. Moreover, ulinastatin treatment significantly decreased the levels of pro-inflammatory factors and peroxides while significantly increasing the levels of anti-inflammatory factors and antioxidants. Mechanistically, ulinastatin treatment inhibited M1 macrophage polarization, achieved by activating the Nrf2 signaling pathway and facilitating Nrf2 nuclear translocation. The application of ML-385 to intercept Nrf2 eliminated ulinastatin-mediated suppression of macrophage M1 polarization and inflammation.
CONCLUSIONS: Ulinastatin protected against both AP and the associated intestinal barrier dysfunction. It suppressed the inflammatory response and oxidative stress by promoting Nrf2 nuclear translocation and inhibiting M1 macrophage polarization through the activation of the Nrf2 signaling pathway.
METHODS: Experimental rats were randomly divided into five subgroups as follows: control, AP, AP + UTI, AP + ML-385 and AP + UTI + ML-385. The pancreatic and intestinal injuries were assessed by enzyme-linked immunosorbent assay (ELISA), western blot, pathology, laser Doppler and transmission electron microscope (TEM). The inflammatory biomarkers were determined by western blot and the indicators of oxidative stress were also measured. The Nrf2 signaling pathway and macrophage polarization were evaluated by immunofluorescence staining, western blot and qRT-PCR analysis.
RESULTS: Ulinastatin treatment effectively improved both AP and AP-associated intestinal barrier dysfunction. Moreover, ulinastatin treatment significantly decreased the levels of pro-inflammatory factors and peroxides while significantly increasing the levels of anti-inflammatory factors and antioxidants. Mechanistically, ulinastatin treatment inhibited M1 macrophage polarization, achieved by activating the Nrf2 signaling pathway and facilitating Nrf2 nuclear translocation. The application of ML-385 to intercept Nrf2 eliminated ulinastatin-mediated suppression of macrophage M1 polarization and inflammation.
CONCLUSIONS: Ulinastatin protected against both AP and the associated intestinal barrier dysfunction. It suppressed the inflammatory response and oxidative stress by promoting Nrf2 nuclear translocation and inhibiting M1 macrophage polarization through the activation of the Nrf2 signaling pathway.